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Summary The pattern of TGFP expression and in vitro response to TGFP has been defined in three ovarian
carcinoma cell lines (PEOl, PE04 and PE014). Marked differences in both mRNA expression and growth
responses were detected between the cell lines. All expressed mRNA for TGFP3, PEOI and PE04 but not
PE014 expressed mRNA for TGFP,, whereas PE014 but not PEOI and PE04 expressed TGFP2. Growth of
PE014 cells in culture was markedly inhibited by both TGFlI and P2, PEOI cells were inhibited by TGFP,
but not TGFP2 whilst growth of PEO4 cells were not affected by exposure to either of these peptides. These
data indicate that several elements of potential autocrine loops involving TGFJ3's are present within ovarian
cancer cells.
The transforming growth factors are increasingly recognised
as important molecules in the regulation of cell growth and
differentiation (Nilsen, 1990; Barnard et al., 1990 for
reviews). Whilst the role of TGF-x has been relatively widely
studied, data on the TGFP's are only now becoming avail-
able. These peptides are generating interest in a variety of
fields including development (Akhurst et al., 1990; Roberts et
al., 1990a), bone remodelling (Noda & Rodan, 1989; Bone-
wald & Mundy, 1990), extracellular matrix production
(Roberts & Sporn, 1989) and the prevention and treatment of
cancer (Colletta, 1990). Research into the biological role of
TGFP's is complicated by the diversity of the peptide family,
with at least three TGF-,B peptides being identified thus far in
the human (Derynck et al., 1985; Arrick et al., 1990) and
additional forms being present in other species (Roberts et
al., 1990b). However, TGFIB has been detected in a wide
range of tissues, including transformed cells (Roberts et al.,
1981), and dependent upon conditions it may be either
stimulatory or inhibitory for cell growth (Roberts et al.,
1985). There are multiple binding proteins for TGFPI's
(Frolik et al., 1984; Massague & Like, 1985; Massague et al.,
1990) and recent data suggest that the growth regulatory
effects of TGFP may be dependent upon the presence of
specific classes of binding proteins (Roberts, 1991).
TGFP appears to play a role in normal ovarian function,
particularly in the regulation of granulosa cell functions in
response to follicle stimulating hormone (Adashi et al., 1989).
However, little is known of the effects of TGFP's and their
expression in ovarian carcinomas. In order to investigate
further the role of TGF,B in ovarian carcinoma cells, we have
developed cell line models and have examined them for the
presence of TGFP mRNA and their growth response to
TGF-P.
Materials and methods
Cell lines
The human ovarian carcinoma cell lines PEO1, PEO4 and
PEO14 were established and characterised as previously des-
cribed (Langdon et al., 1988). They were maintained rou-
tinely at 37'C in a humidified atmosphere of 5% CO2 in air
in RPMI 1640 (Gibco) supplemented with Streptomycin
(100ILg ml '), Penicillin (100 IU ml-') and glutamine (2 mM;
'RPMI') and containing 5% non-charcoal stripped heat-
inactivated foetal calf serum (FCS).
Effects of TGFI31 and TGFP2 on growth ofovarian carcinoma
cell lines
Exponentially growing cells were harvested by trypsinisation
and plated in 24-well plates (Falcon) at densities of approx-
imately 2 x 104 cells/well (four wells per experimental condi-
tion) in RPMI containing 5% FCS. After 24 h, medium was
removed, cells were washed with phosphate buffered saline
(pH 7.4; PBS) and medium replaced with RPMI containing
either 5% double charcoal stripped (DCS), FCS, 0.5% DCS,
FCS or HITS (hydrocortisone 10 nm, insulin 5 ,tg ml-',
transferrin 1Ofig ml-', selenium 30 nm) and incubated for a
further 24 h. Cells were then washed with PBS and medium
replaced with RPMI with the corresponding additives (as
above) with or without human recombinant TGF-P, or por-
cine TGF-P2 (British Biotechnology) added at concentrations
ranging from 0.01 ng ml-' to 1.0 ngml-'. This time point
was designated day 0. Cells were incubated at 37°C for 6
days. Media was replenished on day 3. On days 0, 3, and 6,
cells were harvested by trypsinisation and counted using a
Coulter Counter.
Effects of TGF132 and TGFP2 on the cell cycle in the PE014
cell line
Exponentially growing cells were harvested by trypsinisation
and plated in 6-well plates (Falcon) at densities of approx-
imately 2 x 104 cells well (four wells per experimental condi-
tion) in RPMI containing 5% FCS . After 24 h, medium was
removed, cells were washed with PBS and medium replaced
with RPMI containing 5% DCS, FCS with or without added
growth factor. Cells were harvested by trypsinisation at time
0 and after 24 and 48 h incubation with TGFP, or TGFP2 at
a concentration of 1 ngml-'. The cell suspension was trans-
ferred to plastic tubes containing 0.5 ml FCS (to neutralise
trypsin) and cells centrifuged for 4 min at 500 g at room
temperature, washed in PBS and repelleted. Ethanol (0.5 ml
70%) was added to the cells and pellets stored at -40'C
until required for analysis. Cells were treated with detergent
and the DNA stained with propidium iodide (Vindelov et al.,
1983). Analysis was performed using a FACScan flow cyto-
meter (Becton Dickinson), with gates set to exclude frag-
mented or clumped material and doublets.
mRNA extraction
Exponentially growing cells were harvested from 175 cm2
culture flasks as follows: Cells were washed with ice cold
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PBS, harvested using a cell scraper, suspended in ice cold
PBS (25 ml) and spun down in a bench top centrifuge
(1,000g, 10min). The cell pellet was stored at -70°C until
used for RNA extraction. Using a sterile pasteur pipette the
cell pellet was transferred to a 15 ml tube containing 3M
lithium chloride/6 M urea (6 ml). The homogenate was soni-
cated twice at 4°C for 30 s and stored overnight at 4°C. The
pellet was spun down at 15,000g, 4°C for 30 min. The super-
natant was discarded and the pellet washed with fresh
lithium chloride/urea (6 ml) and centrifuged at 15,000g, 4°C
for 30 min. The pellet was then resuspended in Tris-HCl
(10 mM pH 7.5, 6 ml) SDS (0.5%), with proteinase K (50fig
ml 1, Boehringer Mannheim) added and the sample incubat-
ed at 37°C for 20 min. Following incubation the samples
were extracted using 100% phenol (pre-equilibrated with
0.1 M Tris pH 7.4), this extraction was repeated using
phenol:chloroform: isoamyl-alcohol (25:24:1 v/v/v) and chloro-
form:isoamyl-alcohol (24:1 v/v). Following each extraction
the sample was centrifuged at 2,000g at room temperature
for 10 min and the aqueous phase recovered. After the final
extraction, lithium chloride (300yl 8 M), absolute alcohol
(2.5 volumes) were added and the RNA precipitated over-
night at -20°C. RNA was pelleted by centrifugation at
4,000g, 4°C for 45 min. The supernatant was decanted and
the pellet dried and resuspended in diethylpyrocarbonate
treated water. Optical density measurements at 260 and
280 nm were taken to assess yield and purity of the RNA
preparation.
Synthesis ofriboprobes
Labelled RNA was prepared from linearised template DNA
using a Gemini II system (Promega Ltd, Southampton, UK).
Template DNA was incubated in the presence of an RNAase
inhibitor (Human placental RNAsin; Amersham plc), cold
ribonucleosides, dithiothreitol and 32P-rCTP with the appro-
priate RNA polymerase (T3, T7 or SP6) for 1 h at 37°C. The
DNA template was then removed by incubation with RQ1
DNAase (Promega Ltd) for 15 min at 37°C. Labelled RNA
was precipitated in the presence of added tRNA (Sigma) as
carrier and full length transcripts were isolated by poly-
acrylamide electrophoresis. Following identification of full
length transcripts by autoradiography, the bands were excis-
ed and labelled RNA eluted from the gel, precipitated under
ethanol and resuspended in hybridisation buffer prior to use
in RNAase protection assays.
RNAase protection assay
Test RNA (20rig) was precipitated under ethanol, dried and
resuspended in 30gAl hybridisation buffer (80% formamide,
40 mM Pipes (pH 6.7), 400 mM NaCl, 1 mM EDTA); tRNA
was prepared in a similar manner as a negative control. Test
probe (106 c.p.m.) plus actin probe (106 c.p.m.) were added to
each sample. Samples were incubated at 85°C for 20 min,
transferred to a water bath and left to hybridise overnight at
51°C. After hybridisation, single stranded RNA (both labell-
ed and cold) was removed by incubating with single strand
specific RNAases A and TI (Boehringer Mannheim) at 37°C
for 30 min, followed by incubation with proteinase K in SDS
at 37°C for 15 min. Protein was extracted by using phenol/
chloroform-isoamyl alcohol. Double stranded probe: test
RNA was precipitated with carrier tRNA (5fAg) and separat-
ed by gel electrophoresis. Full length transcripts for test
probes were scored as positive, whilst transcripts for actin
were used as an internal control.
Statistics
Cell growth and cell cycle responses in vitro were analysed
using Wilcoxon Rank test and significant differences at the
P<0.05 level defined.
Results
TGFIp mRNA expression in ovarian carcinoma cell lines
TGFiI mRNA expression was observed only in cell lines
PEOl and PE04, and not in PEO14 cells (Figure 1). In
contrast, expression of mRNA for TGFP2 could not be dem-
onstrated in PEOI or PE04 cell extracts whilst PE014 cells
appeared to express this factor (Figure 2). Finally, TGFP3
mRNA expression was observed in all three cell lines tested
(Figure 3).
Growth responsiveness ofovarian carcinoma cell lines to
TGFp, and TGF132
PEOI TGFI31 was capable of producing significant inhibi-
tory effects on the growth of PEOI cells, but these were small
and observed only under certain culture conditions. Thus, as
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Figure 1 TGFPI mRNA expression: 6% Polyacrylamide gel,
showing bands representing mRNA from TGFP, and human-y-
actin. Lanes 1-3 contain test samples, PEOI and PE04 show
positive hybridisation with TGFPI riboprobe, whilst no signal is
apparent with PE014 mRNA. Lane 4 contains tRNA as a
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Figure 2 TGFP2 mRNA expression: 6% Polyacrylamide gel,
showing bands representing mRNA from TGFP2 and human-y-
actin. PEOI and PE04 show no hybridisation with TGFP2 ribop-
robe, whilst PE014 shows positive hybridisation with this probe.
is shown in Figure 4, significant inhibitory effects were pro-
duced at day 6 but not day 3 by addition of 1 ng ml1'
TGFPI in HITS and 0.1 and 1 ng ml-' TGF,I3 in 0.5% serum
supplemented culture medium. In culture systems containing
5% serum TGFP, produced no significant effect at any time
point. No significant effect ofTGFP2 on the growth of PEOl
cells was observed under any of the conditions tested during
the course of these experiments (data not shown).
PE04 Neither TGFPI nor TGFP2 altered the growth of
PE04 cells under any growth conditions tested (5% or 0.5%
DCS FCS or HITS; Data not shown).
PE014 In contrast to PEOI and PE04, TGFPI3 produced a
significant inhibitory effect on the growth of PE014 in each
of the culture conditions tested. The effects were dose related
and were more pronounced after 6 days of culture. At the
highest doses of TGFi, growth was significantly inhibited
during the first 3 days of exposure of the cells (P<0.05)
whilst by 6 days after initial exposure growth inhibition was
produced by all doses above 0.01 ng ml-' reaching a maxi-
mum at 1 ng ml-' TGFI (P<0.05; Figure 5). These effects
of TGFP, occurred irrespective of the presence or concentra-
tion of serum and were consistent in each of three replicate
experiments (representative experiment shown; Figure 5).
The effects observed with TGFPi2 on the cell line PE014
were similar but less marked than those found with TGF,I,.
Figure 3 TGFP3 mRNA expression: 6% Polyacrylamide gel,
showing bands representing mRNA from TGFP3, PEOI, PE04
and PE014 show positive hybridisation with TGFP3 riboprobe.
Thus higher concentrations of TGFP2 were required for
significant effects to be demonstrated and the degree of
inhibition was less pronounced, nevertheless the observed
effects were consistent in each of three replicate experiments
(representative experiment shown; Figure 6).
Effects ofTGFJP, and TGFP2 on the cell cycle in the PEOJ4
cell line
Short term exposure to either TGFP, or TGFP2 was capable
of producing significant effects on the cell cycle distribution
of PE014 cells (Figure 7). After 24 h an increase in cell
numbers in the GO/GI phase of the cell cycle was observed
(P<0.05) in cells treated with either TGF,I or TGFP2 and in
the case of TGFP, this was associated with a decrease in cell
numbers in S-phase; there were no marked effects upon cell
numbers in the G2/M phases of the cycle at this time.
However, after 48 h exposure to TGFP, or TGFP2 the in-
crease in cell numbers in GO/GI compared with untreated
cells became more pronounced and was associated not only
with decreased cell numbers in S phase, but also a significant
reduction in the proportion of cells in the G2/M phases of
the cell cycle (P<0.05; Figure 7).
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Figure 4 Growth response of PEOl cells to TGFP,: Cell counts
per well of PEOI ovarian carcinoma cells treated with TGFP,.
Solid bars represent untreated cells. Each point represents
mean ± s.e. of quadruplicate points. _ = untreated cells,
= cells exposed to 0.1 ng ml-' and = cells exposed to
1 ng ml- TGFP, respectively over either 3 or 6 days. * = Statis-
tically significant difference with respect to time matched control
(P< 0.05). a, Cells grown in RPMI containing HITS. b, Cells
grown in RPMI containing 0.5% DCS FCS. c, Cells grown in
RPMI containing 5% DCS FCS (see text for details).
Discussion
Evidence is presented here to demonstrate that TGFP's
inhibit cell growth in some, but not all ovarian carcinoma
cell lines in vitro. Whilst both TGFPI and TGFP2 markedly
inhibited the growth of PE014 cells (Figure 5-6), PEOI cells
responded only to TGFP, (Figure 4), and PE04 cells were
unaffected by either peptide.
The responses observed for the ovarian carcinoma cell
lines investigated here contrast with those observed pre-
viously (Marth et al., 1990) in which all four cell lines tested
were inhibited by TGFP2, but the concentrations used were
up to 100-fold higher than those used in the present study.
None of the inhibitory doses used in the present study would
have been effective on these previously tested cell lines
(Marth et al., 1990). It would therefore appear that the
sensitivity of ovarian carcinoma cell lines to TGFPI's varies
considerably between cell lines. Of all ovarian carcinoma cell
lines tested to date, PE014, showed the most marked sen-
Figure 5 Growth response of PEO14 cells to TGFPi,: Cell counts
per well of PEO14 ovarian carcinoma cells treated with TGFPi,.
Solid bars represent untreated cells. Each point represents
mean ± s.e. of quadruplicate points. = untreated cells,
1 = cells exposed to 0.01 ng ml-' and m = cells exposed to
0.1 ngml- ;
= cells exposed to 0.5 ngml-' and =
= cells
exposed to 1.Ongml-' TGFP, respectively over either 3 or 6
days. * = Statistically significant difference with respect to time
matched control (P<0.05). a, Cells grown in RPMI containing
HITS. b, Cells grown in RPMI containing 0.5% DCS FCS. c,
Cells grown in RPMI containing 5% DCS FCS (see text for
details).
sitivity to TGFP's being over 100 times more sensitive to
TGFPI, than other cell lines reported. Treatment with doses
of TGFP between of 0.1 and 1 ng ml', reduced cell pro-
liferation by up 50%.
It has recently been suggested that the growth inhibitory
effects of the TGFI3 family results in an arrest of cells in the
GI phase of the cell cycle (Roberts et al., 1991). The data
obtained for the PE014 cell line support this observation.
Thus within 24 h of administration of either TGFP, or
TGFP2 the proportion of cells in the S phase of the cycle was
markedly reduced, with a concomitant increase in cell
numbers in the GO/GI phase of the cell cycle. By 48 h post
TGFP administration cell numbers in both the S phase and
the G2/M phases of the cell cycle were reduced, with a
further rise in the proportion of cells in the GO/GI phase of
the cell cycle being observed (Figure 7). These data suggests
that any effect on cell division exerted by the TGFPI family
probably occurs in the early part of the cell cycle.
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Figure 6 Growth response of PEO14 cells to TGFP2: Cell counts
per well of PEO14 ovarian carcinoma cells treated with TGFP2.
Solid bars represent untreated cells. Each point represents
mean ± s.e. of quadruplicate points. = untreated cells,
M = cells exposed to 0.01 ng ml-' and E = cells exposed to
0.1 ng ml-'; 1 = cells exposed to 0.5 ng ml' and = cells
exposed to 1.0 ngml-I TGFP2 respectively over either 3 or 6
days. * = Statistically significant difference with respect to time
matched control (P<0.05). a, Cells grown in RPMI containing
HITS. b, Cells grown in RPMI containing 0.5% DCS FCS. c,
Cells grown in RPMI containing 5% DCS FCS (see text for
details).
In addition to the growth inhibitory effects of TGFP's
being targeted primarily in the GI phase of the cycle, data
exists which suggests that such effects are mediated via type
II binding sites for TGFP's on the cell surface (Roberts et al.,
1991). It has been demonstrated (Massague et al., 1990) that
three separate binding proteins exist for the TGFi family.
These proteins, designated class I-III, have yet to be isolated
and purified, and therefore have not yet been sufficiently
characterised to define them as receptors. The cell lines
studied here will provide a useful model for the further
investigation of the relative importance of the different TGF,B
binding proteins.
Data presented here also demonstrate that mRNA's for
the different forms of TGF0 are expressed in ovarian car-
cinoma cell lines and that the expression patterns of TGFP's
vary between the different cell types investigated. Thus cell
lines PEOI and PE04 express TGFP, and TGFP3, whilst the
cell line PE014 expresses TGFP2 and TGFP3. The physio-
Day
Figure 7 Effect of TGFP on the cell cycle of PEO14 cells:
Relative percentages of PEO14 ovarian carcinoma cells treated
with TGFPI or TGFP2 for 24 or 48 h. Each point represents
mean ± s.e. of quadruplicate points = untreated cells,
= cells treated with TGFP,, = =cells treated with
TGFP2. * = Statistically significant difference with respect to time
matched control (P<0.05). a, Percentage cells in GO/G1 phases
of the cell cycle; b, Percentage cells in the S-phase of the cell
cycle. c, Percentage cells in the G2/M phases of the cell cycle (see
text for details).
logical significance of such a variance in types of TGFP
expressed by these differing cell lines remains to be deter-
mined, but may indicate different roles for the different forms
of TGF,B. By investigating both the responsiveness of cells to
TGFP's and the expression of these factors, evidence has
been collected which would suggest that in those cell lines
where both a response to and mRNA for TGFP is observed,
some elements of an autocrine loop exist. This applies partic-
ularly to the cell line PEO14 and probably also to the cell
line PEO1. Both PEO1 and PEO14 cells respond more
markedly to TGFPI than to TGFP2 possibly due to differ-
ences in endogenous expression ofTGFP's and/or their bind-
ing proteins in these cells. Nevertheless the presence of
TGFPi2 mRNA and the marked inhibitory effects of this
peptide on cell growth in PE014 suggest that this cell is
regulated by TGFi2 in an autocrine fashion. Data for PEOI
also suggest the presence of an autocrine loop, this time with
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TGFP,. Further studies to define the level of peptide produc-
tion to establish the presence of TGFP binding proteins and
examine the effects ofTGFP blocking antibodies would be of
interest in determining the relative role of the different forms
of TGFPI and their binding proteins in these putative auto-
crine pathways. TGFPi has been shown to be an autocrine
regulator of breast cancer cells (Arteaga et al., 1988) and in
lymphocyte activation (Lucas et al., 1990) but this loop had
not been previously established for ovarian carcinomas. In
breast cancer, secretion of TGFP occurs under steroid hor-
mone regulation (Knabbe et al., 1987; Colletta, 1991), there-
fore to demonstrate the presence of mRNA for TGFP cells
were grown in the presence of non-charcoal stripped serum.
The physiological and clinical relevance of these findings
remain to be elucidated, however it is known that (1) TGFP
may be a marker of progression to steroid insensitivity in
breast cancer cells (Daly & Darbre, 1990). (2) TGFP has been
implicated in the autocrine regulation of normal ovarian
function (Knecht et al., 1987; Kim & Schomberg, 1989;
Magoffin et al., 1989), and (3) TGF beta has been implicated
in the process of metastasis (Schwarz et al., 1990).
In summary, results from the present study show that
TGFi may be a potential autocrine regulator of ovarian
carcinoma cell division in vitro, in both oestrogen sensitive
(PEOI) and insensitive (PE014) cells. The differential expres-
sion patterns for the various forms of TGFP observed
suggest that these factors may play distinct roles in the
regulation of cell division.
The authors are grateful to Dr P. Darbre and Dr R. Daly (ICRF,
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